AstraZeneca is a company within the Healthcare category. AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. Its primary areas of focus include Oncology, Rare Diseases, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
AstraZeneca was founded in 1999 and is headquartered in Cambridge, UK.
AstraZeneca is part of AstraZeneca PLC.
AstraZeneca is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for AstraZeneca is Strong. Minor factual deltas detected.
AI models classify AstraZeneca as a Challenger. AI names competitors first.
AstraZeneca appeared in 7 of 8 sampled buyer-intent queries (88%). AstraZeneca dominates branded search and is a fixture in general pharmaceutical category queries. The biggest gap is in 'specific symptom' searches where AI might prioritize medical advice sites (Mayo Clinic, WebMD) over manufacturer-specific therapeutic pages.
AstraZeneca is perceived as a research-driven scientific leader and a cornerstone of the UK biotech sector. AI captures its massive scale and therapeutic focus accurately, though it may over-index on its COVID-19 vaccine legacy compared to its larger oncology portfolio. Key gap: While AI correctly identifies the COVID-19 vaccine, it often lags in describing the transition of the vaccine business to a for-profit model or the specific decommissioning of certain vaccine brands in specific markets.
Of 6 key facts verified about AstraZeneca, 6 are well-documented (likely accurate across AI models), 0 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
Real-time clinical trial phase shifts or specific pipeline failures that occurred within the last 3-6 months.
Buyers turn to AstraZeneca for Academic Research Institutions Building In-House Solutions: Universities and government institutes (e.g., NIH) conducting early-stage drug discovery., Outsourced Clinical Management: Contract Research Organizations (CROs) that manage clinical trials and development for smaller firms., among 2 documented problem areas.
Buyers evaluating AstraZeneca typically ask AI models about "top oncology pharmaceutical companies", "who makes the most popular lung cancer drugs", "biggest uk biotech companies", and 3 similar queries.
AstraZeneca's main competitors are Bristol Myers Squibb, Novartis, Pfizer. According to AI models, these are the brands most frequently named alongside AstraZeneca in buyer-intent queries.
AstraZeneca's core products are Tagrisso, Imfinzi, Lynparza, Farxiga, Soliris, Ultomiris, Symbicort.
AstraZeneca uses Enterprise/Custom (Healthcare systems and insurance-based pricing).
AstraZeneca serves Global healthcare providers, hospitals, oncology clinics, and patients with chronic or rare diseases..
AstraZeneca differentiates itself through a massive, high-conversion R&D pipeline specifically in targeted oncology and a dedicated, stand-alone rare disease unit (Alexion).
Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/astrazeneca
Last analyzed: April 10, 2026
Founded: 1999 (Merger)
Headquarters: Cambridge, United Kingdom